Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A study of panitumumab, oxaliplatin, fluorouracil and l-leucovorine as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer. (PANORAMA study)

ABSTRACT: Interventions: FOLFOX+Pmab is repeated every 14 days until meeting the withdrawal criteria. Primary outcome(s): Overall Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Kras Wild-type Metastatic Colorectal Cancer

PROVIDER: 2621394 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effective and safe examination of the mFOLFOX6/panitumumab combination therapy for the purpose of hepatectomizing in patients with KRAS Wild-type advanced colorectal cancer which has unresectable liver metastases - Phase II study -

Project description:Interventions: mFOLFOX6+Pmab is repeated every 14 days until meeting the withdrawal criteria. Primary outcome(s): Overall Response Rate Study Design: Single arm Non-randomized

| 2627040 | ecrin-mdr-crc

Phase II study of panitumumab with FOLFOX or FOLFIRI as 1st line treatment in patients with metastatic colorectal cancer in Japan

Project description:Interventions: The investigators choose the treatment A or Barbitrarily. A: FOLFOX + panitumumab B: FOLFIRI + panitumumab Repeat every 14 days until meeting the withdrawal criteria. Primary outcome(s): Overall response rate (ORR) Study Design: Single arm Non-randomized

| 2620434 | ecrin-mdr-crc